Aprea Therapeutics (NASDAQ:APRE) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Aprea Therapeutics (NASDAQ:APRE) announced its quarterly earnings data on Wednesday. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.01, FiscalAI reports. Aprea Therapeutics had a negative return on equity of 96.33% and a negative net margin of 4,405.59%.

Aprea Therapeutics Stock Performance

Aprea Therapeutics stock traded up $0.06 during midday trading on Thursday, hitting $0.94. 73,746 shares of the company were exchanged, compared to its average volume of 1,632,985. The firm has a market capitalization of $11.64 million, a PE ratio of -0.46 and a beta of 1.48. Aprea Therapeutics has a fifty-two week low of $0.55 and a fifty-two week high of $2.22. The business has a fifty day simple moving average of $0.82 and a two-hundred day simple moving average of $0.92.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on APRE shares. HC Wainwright reduced their price objective on Aprea Therapeutics from $4.00 to $1.20 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Oppenheimer started coverage on Aprea Therapeutics in a research note on Thursday, May 7th. They issued an “outperform” rating and a $5.00 price objective for the company. Wedbush reduced their price objective on Aprea Therapeutics from $7.00 to $6.00 and set an “outperform” rating for the company in a research note on Thursday. Zacks Research upgraded Aprea Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, February 16th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Aprea Therapeutics in a research note on Monday, April 20th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $4.07.

Institutional Trading of Aprea Therapeutics

An institutional investor recently bought a new position in Aprea Therapeutics stock. DRW Securities LLC bought a new position in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 120,651 shares of the company’s stock, valued at approximately $103,000. DRW Securities LLC owned 1.73% of Aprea Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 34.19% of the company’s stock.

Aprea Therapeutics Company Profile

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.